1. Fidelity Contrafund (FCNTX)
Fidelity Contrafund remains a cornerstone for growth-oriented investors in 2025, managed by Will Danoff since 1990. The fund prioritizes large-cap companies with durable competitive advantages, such as Meta Platforms, Berkshire Hathaway, and Microsoft. Its 10-year annualized return of 13.2% (as of early 2025) outpaces the S&P 500 by nearly 1.5 percentage points. The expense ratio is 0.39%, below the category average of 0.95%. Danoff’s strategy focuses on companies with accelerating earnings and secular tailwinds, like AI infrastructure and cloud computing. The fund holds 350–400 stocks, reducing single-stock risk while maintaining conviction in top holdings. For long-term growth, its low turnover (under 30%) minimizes taxable distributions. Ideal for investors with a 10+ year horizon and tolerance for moderate volatility.
2. Vanguard Growth Index Fund (VUG)
VUG offers low-cost exposure to large-cap growth stocks, tracking the CRSP US Large Cap Growth Index. With an expense ratio of 0.04%, it is one of the cheapest options for long-term compounding. Top holdings include Apple, Nvidia, Amazon, and Alphabet. The fund’s 10-year return averages 14.8%, driven by technology and consumer discretionary sectors. Unlike actively managed peers, VUG avoids manager risk and style drift. It holds 230+ stocks, with 40% in tech. The ETF structure provides tax efficiency and liquidity. In 2025, as AI and semiconductor demand persists, VUG’s concentration in mega-cap innovators positions it for continued outperformance. Suitable for buy-and-hold investors seeking market-beating returns without premium fees.
3. T. Rowe Price Blue Chip Growth (TRBCX)
TRBCX, managed by Paul Greene since 2019, invests in established large-cap growth companies with sustainable earnings. Holdings include Microsoft, Amazon, and Eli Lilly. The fund’s 15-year annualized return of 14.1% beats 92% of category peers. Expense ratio: 0.69%. Greene emphasizes companies with high return on invested capital (ROIC) and recurring revenue. The portfolio holds 80–100 stocks, with top 10 comprising 45% of assets. Sector allocation favors technology (35%), healthcare (18%), and consumer cyclical (14%). During 2022’s downturn, TRBCX lost 32% but rebounded 48% in 2023–2024. For long-term growth, its disciplined valuation framework avoids bubble stocks. Best for investors comfortable with concentrated, high-conviction bets.
4. Schwab U.S. Large-Cap Growth ETF (SCHG)
SCHG tracks the Dow Jones U.S. Large-Cap Growth Total Stock Market Index, offering broad exposure at a 0.04% expense ratio. It holds 250+ stocks, with Nvidia, Microsoft, and Apple as top positions. The fund’s 10-year return of 14.5% slightly trails VUG but provides better diversification across mid-cap growth names like Palo Alto Networks and ServiceNow. SCHG’s tax efficiency is superior due to low turnover (under 20%). In 2025, its tilt toward semiconductors and software aligns with digital transformation trends. The ETF’s tight bid-ask spread suits dollar-cost averaging. For long-term investors, SCHG combines rock-bottom costs with exposure to emerging growth leaders. Avoid if you seek dividend income—yield is just 0.6%.
5. American Funds Growth Fund of America (AGTHX)
AGTHX, one of the largest mutual funds with $250B in assets, takes a multi-manager approach. Three managers (Donald O’Neal, Barry Crosthwaite, and Claudia Huntington) oversee a portfolio of 300+ growth stocks. Holdings include Broadcom, UnitedHealth, and Mastercard. The fund’s 20-year annualized return of 11.8% surpasses the S&P 500 by 1.2 points. Expense ratio: 0.61%. AGTHX balances mega-cap stability with mid-cap upside (e.g., KKR, Motorola Solutions). Its 12% annual turnover reduces capital gains distributions. In 2025, the fund’s exposure to healthcare innovation (e.g., Vertex Pharmaceuticals) and fintech (e.g., Visa) offers growth beyond tech. Best for investors seeking active management with lower volatility than pure tech funds.
6. Invesco QQQ Trust (QQQ)
QQQ tracks the Nasdaq-100 Index, providing pure exposure to the 100 largest non-financial companies on Nasdaq. Expense ratio: 0.20%. Top holdings: Microsoft, Apple, Nvidia, Amazon, and Broadcom. The fund’s 15-year return of 17.3% crushes broad market indices. QQQ’s 50% tech weighting and 20% communication services tilt make it a high-octane growth vehicle. In 2025, AI chip demand and cloud capex drive earnings for Nvidia, AMD, and Marvell. QQQ’s liquidity ($250B AUM) ensures tight spreads. Risks: concentration (top 10 = 50% of assets) and sensitivity to rate hikes. For long-term growth, QQQ suits investors betting on innovation leaders. Use as a satellite holding, not a core position.
7. Fidelity Blue Chip Growth Fund (FBGRX)
FBGRX, managed by Sonu Kalra since 2009, focuses on large-cap growth with a mid-cap twist. Holdings include Nvidia, Microsoft, and Uber. The fund’s 10-year return of 16.1% ranks in the top 5% of category. Expense ratio: 0.47%. Kalra seeks companies with “positive inflection points”—accelerating revenue or margin expansion. The portfolio holds 250+ stocks, with 30% in tech and 15% in healthcare. Notable positions: Eli Lilly (obesity drugs), Axon Enterprise (law enforcement tech), and Celsius Holdings (energy drinks). Turnover is 40%, higher than index funds but justified by active bets. In 2025, FBGRX’s exposure to GLP-1 drugs and AI infrastructure offers dual growth engines. Best for investors wanting aggressive growth with professional oversight.
8. Vanguard Russell 1000 Growth ETF (VONG)
VONG tracks the Russell 1000 Growth Index, holding 450+ large- and mid-cap growth stocks. Expense ratio: 0.07%. Top holdings overlap with VUG (Apple, Nvidia, Microsoft) but include mid-cap names like DexCom and Copart. The fund’s 10-year return of 14.6% matches VUG while offering slightly better diversification. VONG’s 0.5% dividend yield appeals to growth-at-reasonable-price (GARP) investors. In 2025, its 12% allocation to healthcare (e.g., Intuitive Surgical, Regeneron) hedges tech concentration. The ETF’s tax efficiency and low turnover (15%) suit taxable accounts. For long-term growth, VONG is a set-and-forget core holding. Avoid if you need income or prefer equal-weight strategies.
9. PRIMECAP Odyssey Growth Fund (POGRX)
POGRX, managed by PRIMECAP’s team since 2004, takes a contrarian growth approach. Holdings include Eli Lilly, Microsoft, and Amgen. The fund’s 15-year return of 13.7% beats 88% of peers. Expense ratio: 0.62%. Unlike momentum-driven funds, POGRX buys out-of-favor growth stocks with temporary headwinds—e.g., biotech after patent cliffs or tech after earnings misses. The portfolio holds 150–200 stocks, with 25% in healthcare and 20% in tech. Turnover is just 10%, minimizing taxes. In 2025, its stakes in Novo Nordisk (obesity drugs) and ASML (lithography) reflect long-term thematic bets. The fund closed to new investors in 2023 but reopened in 2024. Best for patient investors who tolerate short-term underperformance for long-term alpha.
10. iShares Core S&P U.S. Growth ETF (IUSG)
IUSG tracks the S&P 900 Growth Index, offering exposure to 500+ large- and mid-cap growth stocks. Expense ratio: 0.04%. Top holdings: Nvidia, Microsoft, Apple, Amazon, and Meta. The fund’s 10-year return of 14.3% slightly trails VUG but includes mid-cap growth like Fortinet and Old Dominion Freight Line. IUSG’s sector weights: tech (40%), healthcare (15%), consumer discretionary (14%). In 2025, its 8% allocation to financials (e.g., Mastercard, PayPal) provides diversification. The ETF’s 0.7% yield exceeds pure tech funds. Liquidity is strong ($10B AUM). For long-term growth, IUSG combines low costs with broad mid-cap exposure. Rebalance annually to lock in gains. Avoid if you already hold VUG or SCHG—overlap exceeds 70%.
